India’s Glenmark Pharma has added to its oncology pipeline by licensing rights to a checkpoint inhibitor from China’s Jiangsu Alphamab Biopharmaceuticals and 3D Medicines in markets outside North America and Europe.
Copyright © 2024 | WordPress Theme by MH Themes